News & Perspective

Feb 08, 2019

Feb 08, 2019

ASP Scan (Weekly) for Feb 08, 2019

Inadequate TB drug-susceptibility testing
New UK guidance on antibiotics for acute cough
FDA to review new Merck antibiotics
CARB-X novel antibiotic funding
Antibiotic prescribing intervention in China
Candida auris fungemia
Microbiology test use in Norway
CRP-guided therapy
Formulary restriction policy
New CARB-X funding

Jul 27, 2018

Jul 27, 2018

ASP Scan (Weekly) for Jul 27, 2018

Iowa State AMR research center
Gram-negative ICU infections
Firm pares antibiotic R&D
Antibiotics for kids' LRTIs
Colistin resistance risk factors
Antifungal use in US hospitals
Pathogens in hurricane floodwaters
Antibiotic resistance in leeches
Candida auris uptick
MCR-1 on hospital surfaces
Antibiotic use in livestock
Forgotten antibiotics
ESBL colonization in travelers
Antibiotic redosing
Resistance trends in Swiss nursing homes
Antibiotic legislation nixed

Nov 17, 2017

Nov 17, 2017

ASP Scan (Weekly) for Nov 17, 2017

Primary care stewardship
No-touch superbug disinfection
Surgical antimicrobial prescribing
Ceftriaxone-resistant gonorrhea
E coli ST131
Single-room ICU design
ECDC CRE guidance
European research funding
Optimal MDR-TB treatment
Real-time resistance tracker
Salmonella in calves
Drug-resistant malaria controversy
US AMR progress
Antimicrobial use in Northern Ireland
Resistance in space

May 11, 2015

May 11, 2015
Smiling Ebola nurse

Liberia declared Ebola-free as panel reviews WHO response

Experts in Geneva map out research plans, and US advisors meet about vaccine licensure.

Jan 05, 2015

Jan 05, 2015
UNMEER's Banbury and Alpha Conde

Ebola deaths top 8,000; exposures trigger health worker evacuations

As deaths top 8,000, UNMEER leadership changes hands, and Guinea launches a new effort.

May 19, 2008

May 19, 2008

EU approves its first prepandemic H5N1 vaccine

(CIDRAP News) – An H5N1 influenza vaccine made by the British pharmaceutical company GlaxoSmithKline (GSK) has become the first prepandemic vaccine to be licensed by the European Union (EU), the company announced today.

Nov 15, 2007

Nov 15, 2007

THE PANDEMIC VACCINE PUZZLE Can we vaccinate enough people in time to matter?

Maryn McKennaContributing Writer

(CIDRAP News) – This in-depth article investigates the prospects for development of vaccines to head off the threat of an influenza pandemic posed by the H5N1 avian influenza virus. Its seven parts put advances in vaccine technology in perspective by illuminating the formidable barriers to producing an effective and widely usable vaccine in a short time frame.

Oct 26, 2007

Oct 26, 2007

THE PANDEMIC VACCINE PUZZLE Part 2: Vaccine production capacity falls far short

Editor's note: This is the second in a seven-part series investigating the prospects for development of vaccines to head off the threat of an influenza pandemic posed by the H5N1 avian influenza virus. The series puts promising advances in vaccine technology in perspective by illuminating the formidable barriers to producing large amounts of an effective and widely usable vaccine in a short time frame.

Pages

Sort Results By:

 Sort Results By:

Narrow results by:

by organization

Newsletter Sign-up

Get CIDRAP news and other free newsletters.

Sign up now»

OUR UNDERWRITERS

Unrestricted financial support provided by

Bentson Foundation 3MAccelerate DiagnosticsGilead 
Grant support for ASP provided by


bioMérieux

  Become an underwriter»